$REVB
REVELATION BIOSCIENCES, INC.

2022 Q1 Form 10-Q Financial Statement

#000095017022009906 Filed on May 16, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1 2021
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.906M $468.9K $3.088M
YoY Change 519.81% 2022.65%
% of Gross Profit
Research & Development $3.680M $1.557M $6.915M
YoY Change 136.36% 304.99%
% of Gross Profit
Depreciation & Amortization $6.262K $642.00 $16.78K
YoY Change 875.39%
% of Gross Profit
Operating Expenses $6.586M $2.608M $3.088M
YoY Change 152.57% 2022.65%
Operating Profit -$6.586M -$2.608M -$11.95M
YoY Change 152.57%
Interest Expense -$15.32K -$52.00K
YoY Change
% of Operating Profit
Other Income/Expense, Net -$30.24K -$4.642K $1.010M
YoY Change 551.46% -167.57%
Pretax Income -$6.617M $1.178M -$2.131M
YoY Change -661.59% 30.67%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings -$6.617M -$2.612M -$2.131M
YoY Change 153.28% 30.67%
Net Earnings / Revenue
Basic Earnings Per Share -$15.90 -$42.50
Diluted Earnings Per Share -$465.9K $647.5K -$1.171M
COMMON SHARES
Basic Shares Outstanding 416.2K 282.0K
Diluted Shares Outstanding 416.2K 282.0K

Balance Sheet

Concept 2022 Q1 2021 Q1 2021
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.186M $390.7K $78.53K
YoY Change 1739.56% -85.38%
Cash & Equivalents $7.200M $10.02M $78.53K
Short-Term Investments $390.7K $0.00
Other Short-Term Assets $684.8K $124.5K $4.830K
YoY Change 449.98% -95.77%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $7.871M $515.2K $83.37K
YoY Change 1427.88% -87.2%
LONG-TERM ASSETS
Property, Plant & Equipment $108.9K $130.1K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $73.51M
YoY Change
Other Assets $48.30M
YoY Change -34.29%
Total Long-Term Assets $108.9K $73.51M $48.30M
YoY Change -99.85% -34.29%
TOTAL ASSETS
Total Short-Term Assets $7.871M $515.2K $83.37K
Total Long-Term Assets $108.9K $73.51M $48.30M
Total Assets $7.980M $74.03M $48.39M
YoY Change -89.22% -34.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.461M $383.6K $596.3K
YoY Change 280.79% -31.14%
Accrued Expenses $3.706M $2.322M
YoY Change 6774.47%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $774.4K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.078M $2.121M $5.486M
YoY Change 280.86% 59.78%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.911M $2.911M
YoY Change 0.0%
Total Long-Term Liabilities $0.00 $2.911M $2.911M
YoY Change -100.0% 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.078M $2.121M $5.486M
Total Long-Term Liabilities $0.00 $2.911M $2.911M
Total Liabilities $8.078M $5.032M $8.397M
YoY Change 60.53% 32.35%
SHAREHOLDERS EQUITY
Retained Earnings -$21.10M
YoY Change
Common Stock $15.08K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$98.51K $8.906M $39.99M
YoY Change
Total Liabilities & Shareholders Equity $7.980M $74.03M $48.39M
YoY Change -89.22% -34.76%

Cashflow Statement

Concept 2022 Q1 2021 Q1 2021
OPERATING ACTIVITIES
Net Income -$6.617M -$2.612M -$2.131M
YoY Change 153.28% 30.67%
Depreciation, Depletion And Amortization $6.262K $642.00 $16.78K
YoY Change 875.39%
Cash From Operating Activities -$4.830M -$2.382M -$725.6K
YoY Change 102.77% 234.91%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $99.10K -$132.0K
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $134.6K $25.74M
YoY Change -134.77%
Cash From Investing Activities $0.00 -$99.10K $25.74M
YoY Change -100.0% -134.77%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $35.50M $600.0K
YoY Change 5816.71%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.74M 8.005M -24.95M
YoY Change 34.19% -133.59%
NET CHANGE
Cash From Operating Activities -4.830M -2.382M -725.6K
Cash From Investing Activities 0.000 -99.10K 25.74M
Cash From Financing Activities 10.74M 8.005M -24.95M
Net Change In Cash 5.912M 5.524M 66.80K
YoY Change 7.02% 469.48%
FREE CASH FLOW
Cash From Operating Activities -$4.830M -$2.382M -$725.6K
Capital Expenditures $0.00 $99.10K -$132.0K
Free Cash Flow -$4.830M -$2.481M -$593.7K
YoY Change 94.67% 174.01%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001810560
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-39603
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
REVELATION BIOSCIENCES, INC.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-3898466
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
4660 La Jolla Village Drive
CY2022Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92122
CY2022Q1 dei City Area Code
CityAreaCode
650
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
800-3717
CY2022Q1 dei Security12b Title
Security12bTitle
Common stock, par value $0.001 per share
CY2022Q1 dei Trading Symbol
TradingSymbol
REVB
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q1 dei Entity Bankruptcy Proceedings Reporting Current
EntityBankruptcyProceedingsReportingCurrent
true
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
15082771
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7186261
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1274729
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
684780
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
637342
CY2022Q1 us-gaap Assets Current
AssetsCurrent
7871041
CY2021Q4 us-gaap Assets Current
AssetsCurrent
1912071
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
108919
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
115181
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
14960
CY2022Q1 us-gaap Assets
Assets
7979960
CY2021Q4 us-gaap Assets
Assets
2042212
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1460845
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
596261
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3706366
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1528669
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
16752
CY2022Q1 revb Deferred Underwriting Commissions
DeferredUnderwritingCommissions
2911260
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
8078471
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2141682
CY2022Q1 us-gaap Liabilities
Liabilities
8078471
CY2021Q4 us-gaap Liabilities
Liabilities
2141682
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
6933593
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
29977303
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15082771
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15082771
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12944213
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12944213
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
15083
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
2309
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
21020246
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-21133840
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-14517299
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-98511
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-99470
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7979960
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2042212
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3680280
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1557039
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2906020
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1050672
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
6586300
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
2607711
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6586300
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2607711
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-30241
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4642
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-30241
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4642
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-6616541
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2612353
CY2022Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.47
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.42
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14201955
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6290262
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
3411624
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
99998
CY2021Q1 revb Stock Issued During Period Value New Issuance Of Series A1 Preferred Stock
StockIssuedDuringPeriodValueNewIssuanceOfSeriesA1PreferredStock
3904872
CY2021Q1 revb Payment For Series A Preferred Stock Subscribed
PaymentForSeriesAPreferredStockSubscribed
3499997
CY2021Q1 revb Payment For Common Stock Subscribed
PaymentForCommonStockSubscribed
499998
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
102325
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2612353
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
8906461
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-99470
CY2022Q1 revb Conversion Of Series A Preferred Stock To Common Stock
ConversionOfSeriesAPreferredStockToCommonStock
-3903730
CY2022Q1 revb Conversionofseriesa1 Preferredstocktocommonstock
Conversionofseriesa1Preferredstocktocommonstock
-3578197
CY2022Q1 revb Issuance Of Common Stock In Connection With The Business Combination Net Of Issuance Costs
IssuanceOfCommonStockInConnectionWithTheBusinessCombinationNetOfIssuanceCosts
14346254
CY2022Q1 revb Equity Issuance For Fees In Connection With Business Combination
EquityIssuanceForFeesInConnectionWithBusinessCombination
300
CY2022Q1 revb Proceeds From Pipe Investment Net Issuance Costs
ProceedsFromPipeInvestmentNetIssuanceCosts
7262219
CY2022Q1 revb Issuance Of Warrants In Connection With Pipe Investment
IssuanceOfWarrantsInConnectionWithPipeInvestment
3634262
CY2022Q1 revb Issuance Of Placement Agent Warrants In Connection With Pipe Investment
IssuanceOfPlacementAgentWarrantsInConnectionWithPipeInvestment
508797
CY2022Q1 revb Rollover Warrant Exercise
RolloverWarrantExercise
5074
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-99101
CY2022Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
2500000
CY2022Q1 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
2500000
CY2022Q1 revb Proceeds From Business Combination Financing Activity
ProceedsFromBusinessCombinationFinancingActivity
11923499
CY2022Q1 revb Proceeds From Pipe Investment Financing Activity
ProceedsFromPipeInvestmentFinancingActivity
7262219
CY2021Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
67344
CY2021Q1 revb Issuance Of Warrants In Connection With Series A1 Preferred Stock
IssuanceOfWarrantsInConnectionWithSeriesA1PreferredStock
326675
CY2021Q1 revb Deferred Offering Costs Included In Accounts Payable And Accrued Expenses
DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
155452
CY2022Q1 revb Repurchase For The Forward Share Purchase Agreement Exercise
RepurchaseForTheForwardSharePurchaseAgreementExercise
-7652325
CY2022Q1 revb Pre Funded Warrants Exercise
PreFundedWarrantsExercise
13
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
137892
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-6616541
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-98511
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-6616541
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2612353
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
137892
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
102325
CY2022Q1 us-gaap Depreciation
Depreciation
6262
CY2021Q1 us-gaap Depreciation
Depreciation
642
CY2022Q1 revb Non Cash Lease Expense
NonCashLeaseExpense
14960
CY2021Q1 revb Non Cash Lease Expense
NonCashLeaseExpense
9330
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
42604
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1144
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
258515
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
218754
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1391282
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-93667
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-16752
CY2021Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-8227
CY2022Q1 revb Increase Decrease In Accrued Interest Notes Payable And Convertible Note
IncreaseDecreaseInAccruedInterestNotesPayableAndConvertibleNote
36920
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4830066
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2382052
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
99101
CY2022Q1 revb Repurchase For The Forward Share Purchase Agreement Exercise
RepurchaseForTheForwardSharePurchaseAgreementExercise
-7652325
CY2022Q1 revb Repayments Of Notes Payable Including Interest Expenses
RepaymentsOfNotesPayableIncludingInterestExpenses
-796882
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
599996
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10741598
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8004865
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
5911532
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
5523712
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1274729
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4492400
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7186261
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10016122
CY2022Q1 revb Noncash Or Part Non Cash Acquisition Current Liabilities Assumed
NoncashOrPartNonCashAcquisitionCurrentLiabilitiesAssumed
2149432
CY2022Q1 revb Deferred Underwriting Commissions Assumed In Business Combination
DeferredUnderwritingCommissionsAssumedInBusinessCombination
2911260
CY2022Q1 revb Noncash Equity Issuance For Fees Upon Business Combination
NoncashEquityIssuanceForFeesUponBusinessCombination
300
CY2022Q1 revb Noncash Issuance Of Common Warrants Pipe Investment
NoncashIssuanceOfCommonWarrantsPipeInvestment
3634262
CY2022Q1 revb Noncash Issuance Of Placement Agent Warrants With Pipe Investment
NoncashIssuanceOfPlacementAgentWarrantsWithPipeInvestment
508797
CY2022Q1 revb Noncash Or Part Noncash Premium Financing Agreement
NoncashOrPartNoncashPremiumFinancingAgreement
513333
CY2022Q1 revb Interest Incurred
InterestIncurred
14383
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14441532
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4207776
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-6600000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-21100000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-98511
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7200000
CY2021Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
131963
CY2022Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
131963
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the condensed consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions about future events that affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of expenses. These estimates and assumptions are based on the Company’s best estimates and judgment. The Company regularly evaluates its estimates and assumptions using historical and industry experience and other factors; however, actual results could differ materially from these estimates and could have an adverse effect on the Company’s condensed consolidated financial statements.</span></p>
CY2022Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents. Bank deposits are held by accredited financial institutions and these deposits may at times be in excess of federally insured limits. The Company limits its credit risk associated with cash and cash equivalents by placing them with financial institutions that it believes are of high quality. The Company has not experienced any losses on its deposits of cash or cash equivalents.</span></p>
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
131963
CY2021Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
1528669
CY2022Q1 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P5Y
CY2022Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
167867
CY2022Q1 us-gaap Common Unit Issued
CommonUnitIssued
12944213
CY2022Q1 us-gaap Common Unit Outstanding
CommonUnitOutstanding
1294421
CY2022Q1 revb Aggregate Shares Of Common Stock
AggregateSharesOfCommonStock
3072870
CY2022Q1 us-gaap Shares Issued
SharesIssued
3480692
CY2022Q1 us-gaap Stock Option Exercise Price Increase
StockOptionExercisePriceIncrease
10.20
CY2022Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
35500000
CY2022Q1 revb Escrowed Amount
EscrowedAmount
7700000
CY2022Q1 revb Released Amount
ReleasedAmount
4200000
CY2021Q4 revb Accrued Clinical Study Expenses
AccruedClinicalStudyExpenses
327244
CY2022Q1 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
848223
CY2021Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
294130
CY2022Q1 revb Accrued Clinical Development Costs
AccruedClinicalDevelopmentCosts
110566
CY2021Q4 revb Accrued Clinical Development Costs
AccruedClinicalDevelopmentCosts
145566
CY2021Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
5000
CY2022Q1 revb Premium Finance Agreement
PremiumFinanceAgreement
513333
CY2022Q1 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
3706366
CY2021Q4 revb Prepaid Clinical Costs Current
PrepaidClinicalCostsCurrent
488614
CY2022Q1 us-gaap Prepaid Insurance
PrepaidInsurance
618750
CY2022Q1 revb Other Prepaid Expense And Current Assets
OtherPrepaidExpenseAndCurrentAssets
66030
CY2021Q4 revb Other Prepaid Expense And Current Assets
OtherPrepaidExpenseAndCurrentAssets
148728
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
684780
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
637342
CY2022Q1 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
131963
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
23044
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
16782
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
108919
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
115181
CY2022Q1 us-gaap Depreciation
Depreciation
6262
CY2021 us-gaap Depreciation
Depreciation
16782
CY2022Q1 us-gaap Employee Related Liabilities Current And Noncurrent
EmployeeRelatedLiabilitiesCurrentAndNoncurrent
978343
CY2021Q4 us-gaap Employee Related Liabilities Current And Noncurrent
EmployeeRelatedLiabilitiesCurrentAndNoncurrent
756729
CY2022Q1 revb Accrued Clinical Study Expenses
AccruedClinicalStudyExpenses
1255901
CY2022Q1 revb Common Stock Transferred
CommonStockTransferred
245019
CY2022Q1 revb Expense Incurred For Upfront Monthly And Interest Payments
ExpenseIncurredForUpfrontMonthlyAndInterestPayments
208440
CY2022Q1 revb Cash Paid For Upfront Monthly And Interest Payments Under Finance Agreement
CashPaidForUpfrontMonthlyAndInterestPaymentsUnderFinanceAgreement
313857
CY2022Q1 us-gaap Contractual Obligation Future Minimum Payments Due Remainder Of Fiscal Year
ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear
520999
CY2022Q1 us-gaap Noninterest Expense Investment Advisory Fees
NoninterestExpenseInvestmentAdvisoryFees
2700000
CY2022Q1 revb Noninterest Expense Investment Advisory Fees In Form Of Equity
NoninterestExpenseInvestmentAdvisoryFeesInFormOfEquity
2600000
CY2022Q1 revb Transaction Expenses
TransactionExpenses
8500000
CY2022Q1 revb Deferred Underwriting Fees
DeferredUnderwritingFees
1500000
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Common Unit Outstanding
CommonUnitOutstanding
21136
CY2022Q1 revb Public Warrants Outstanding
PublicWarrantsOutstanding
21136
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
29977303
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
6292140
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6100000
CY2020 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
37000
CY2022Q1 us-gaap Proceeds From Previous Acquisition
ProceedsFromPreviousAcquisition
11900000
CY2022Q1 revb Escrowed Amount
EscrowedAmount
7700000
CY2022Q1 revb Released Amount
ReleasedAmount
4200000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15082771
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15082771
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12944213
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12944213
CY2022Q1 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
0
CY2022Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
15381501
CY2021Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4207776
CY2022Q1 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
2.725
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
137892
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
102325
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0

Files In Submission

Name View Source Status
0000950170-22-009906-index-headers.html Edgar Link pending
0000950170-22-009906-index.html Edgar Link pending
0000950170-22-009906.txt Edgar Link pending
0000950170-22-009906-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
revb-20220331.htm Edgar Link pending
revb-20220331.xsd Edgar Link pending
revb-20220331_cal.xml Edgar Link unprocessable
revb-20220331_def.xml Edgar Link unprocessable
revb-20220331_htm.xml Edgar Link completed
revb-20220331_lab.xml Edgar Link unprocessable
revb-20220331_pre.xml Edgar Link unprocessable
revb-ex31_1.htm Edgar Link pending
revb-ex31_2.htm Edgar Link pending
revb-ex32_1.htm Edgar Link pending
revb-ex32_2.htm Edgar Link pending
Show.js Edgar Link pending